MedTrace Logo

CsA vs MMC for Preventing Pterygium Recurrence

NCT06944132 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-04-25

No results posted yet for this study

Summary

aimed to compare the efficacy and safety of topical cyclosporin A (CsA) versus mitomycin C (MMC) as adjunctive therapies in preventing pterygium recurrence after surgical excision.

Conditions

  • Pterygium
  • Pterygium of the Conjunctiva and Cornea

Interventions

PROCEDURE

Excision of the pterygium

The surgical procedure involved excision of the pterygium, including the fibrovascular head and associated conjunctival tissue, followed by bare sclera closure using an autologous conjunctival graft harvested from the superior bulbar conjunctiva. The graft was secured in place using either fibrin glue or 8-0 absorbable sutures. In Group B, 0.02% mitomycin C (MMC) was applied to the bare sclera for two minutes using a soaked sponge, followed by thorough irrigation with balanced salt solution.

DRUG

Post-operative application of CsA

Patients received topical cyclosporin A (0.05%) twice daily for three months postoperatively.

DRUG

Intra-operative application of MMC

0.02% mitomycin C (MMC) was applied to the bare sclera for two minutes using a soaked sponge, followed by thorough irrigation with balanced salt solution.

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Ehab Saad, Lecturer · Benha University, Ebsar Eye Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2024-09-30
Completion
2024-10-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06944132 on ClinicalTrials.gov